Akèy › Kansè Ezofajyen › Ohio
Etid klinik pou Kansè Ezofajyen nan Ohio
22 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- ak 1 plis
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- ak 44 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07814248DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000Pan-tumor MRD Study
- Gabrail Cancer Center, Canton
- Taylor Cancer Research Center, Maumee
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
- Cleveland Clinic, Cleveland
- Kettering, Kettering
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07217704EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06263088ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07431281The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
- University Hospitals of Cleveland, Cleveland
- Cleveland Clinic, Cleveland
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT00288119A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou Jul 6, 2026 · NCT06710756Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Taylor Cancer Research Center (site 204), Maumee
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Dec 11, 2025 · NCT03556228A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Dec 11, 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT0345277464Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 1/2
Laj 15 ak plis · Tout sèks · Mizajou Aug 12, 2025 · NCT06298916Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.